On Friday, Avidity Biosciences Inc (NASDAQ: RNA) was 5.36% up from the session before settling in for the closing price of $29.08. A 52-week range for RNA has been $14.75 – $56.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 49.32% over the past five years. When this article was written, the company’s average yearly earnings per share was at -38.89%. With a float of $111.07 million, this company’s outstanding shares have now reached $119.89 million.
Let’s look at the performance matrix of the company that is accounted for 391 employees. In terms of profitability, gross margin is 80.79%, operating margin of -3209.35%, and the pretax margin is -2772.45%.
Avidity Biosciences Inc (RNA) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Avidity Biosciences Inc stocks. The insider ownership of Avidity Biosciences Inc is 7.61%, while institutional ownership is 103.86%. The most recent insider transaction that took place on Feb 03 ’25, was worth 188,918. In this transaction Chief Program Officer of this company sold 5,875 shares at a rate of $32.16, taking the stock ownership to the 50,554 shares. Before that another transaction happened on Feb 03 ’25, when Company’s Officer proposed sale 17,625 for $32.93, making the entire transaction worth $580,391.
Avidity Biosciences Inc (RNA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.94 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -38.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.15% during the next five years compared to -34.37% drop over the previous five years of trading.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
You can see what Avidity Biosciences Inc (RNA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 15.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 337.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.90, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -4.74 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Avidity Biosciences Inc (NASDAQ: RNA) saw its 5-day average volume 1.46 million, a positive change from its year-to-date volume of 1.35 million. As of the previous 9 days, the stock’s Stochastic %D was 23.30%. Additionally, its Average True Range was 1.84.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 13.33%, which indicates a significant decrease from 33.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.05% in the past 14 days, which was lower than the 60.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.17, while its 200-day Moving Average is $38.62. Nevertheless, the first resistance level for the watch stands at $31.49 in the near term. At $32.34, the stock is likely to face the second major resistance level. The third major resistance level sits at $33.91. If the price goes on to break the first support level at $29.07, it is likely to go to the next support level at $27.50. The third support level lies at $26.65 if the price breaches the second support level.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
There are 119,309K outstanding shares of the company, which has a market capitalization of 3.68 billion. As of now, sales total 9,560 K while income totals -212,220 K. Its latest quarter income was 2,340 K while its last quarter net income were -80,400 K.
